FGFR1 and intrahepatic cholangiocarcinoma: While 3 FGFR1-3/4 inhibitors are approved for the treatment of ICC (3), positive trial results are tempered by a short duration of disease control (less than 9 months) and limited response rates (18%–42%) (4).